脂蛋白a与钙化性主动脉瓣狭窄发生发展的关系及高脂蛋白a血症相关治疗的研究进展
Research progress in relationship between lipoprotein(a)and occurrence and development of calcific aortic valve stenosis and related treatment of hyperlipoprotein Aemia
张莉 1张梦圆 2夏彬凤 1孔敏 1王茹 1黄慧慧 1尹霞1
作者信息
- 1. 吉林大学第一医院心血管内科,吉林 长春 130021
- 2. 吉林大学第一医院呼吸与危重症医学科,吉林 长春 130021
- 折叠
摘要
脂蛋白a[Lp(a)]是由载脂蛋白A(apo A)、apo B100和胆固醇酯核心共同组成的高度多态性脂蛋白分子;钙化性主动脉瓣狭窄(CAVS)是由环境和遗传因素共同参与的多因素心脏瓣膜病,Lp(a)是CAVS发病的独立危险因素,可增加CAVS的发病风险.Lp(a)在CAVS的治疗过程中发挥重要作用,尽管目前临床上仍以手术作为CAVS的主要治疗手段,但随着对其病理机制的深入探索,以Lp(a)为潜在治疗靶点的药物治疗也成为一种新的方法.现就Lp(a)的结构、特点及其在CAVS发生发展中的作用、高脂蛋白a血症相关治疗和通过抵抗炎症对CAVS进行预防及治疗的研究进行综述,提高临床医生对高脂蛋白a血症的了解和重视,为CAVS的预防及靶向药物治疗提供新的思路.
Abstract
Lipoprotein(a)[Lp(a)]is a highly polymorphic lipoprotein molecule composed of apolipoprotein A(apo A),apo B100,and cholesterol ester core;calcific aortic valve stenosis(CAVS)is a multifactorial valvular heart disease influenced by both environmental and genetic factors.Lp(a)is an independent risk factor for CAVS and can increase the onset risk of CAVS.Lp(a)plays an important role in the treatment of CAVS.Although surgery is currently the main clinical treatment for CAVS,with further exploration into its pathological mechanism,drug therapy targeting Lp(a)has emerged as a new method.This paper reviews studies about the structure and characteristics of Lp(a),its role in the occurrence and development of CAVS,treatment options related to hyperlipoprotein Aemia,and the studies preventing and treating CAVS by combating inflammation,and enhances the clinicians'understanding and awareness of hyperlipoprotein Aemia and provides new insights for the prevention and targeted drug therapy of CAVS.
关键词
脂蛋白a/钙化性主动脉瓣狭窄/主动脉瓣钙化/高脂蛋白a血症Key words
Lipoprotein(a)/Calcific aortic valve stenosis/Aortic valve calcification/Hyperlipoprotein Aemia引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据